Clinical trial NCT03847610: Minimally Invasive Sensing of Beta-lactam Antibiotics
Official title: Microneedle Sensing of Beta-lactam Antibiotic Concentrations in Human Interstitial Fluid
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Pharmacokinetics
Penicillin V
Penicillins
Proof of Concept Study
Clinical Trial, Phase I
Microneedle array
Lead sponsor: Imperial College London
Sponsor class: OTHER
First posted: 2019-02-20
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This study is an in-house feasibility study of a microneedle biosensor developed within Imperial College London.

Detailed description: Outline of the study:

This study will comprise the recruitment of 10-15 healthy volunteers. They will be recruited to test the microneedle biosensors and undergo rich plasma sampling with or without tissue microdialysis to calibrate the microneedle biosensor and evaluate its accuracy against current gold standards (i.e. plasma drug concentration and tissue microdialysis). This study will take place at the Imperial Clinical Research Facility (CRF).

Patient identification:

Healthy volunteers will be recruited from a healthy volunteer database held within Imperial College London and via identification of participants within the College. An initial advertisement e-mail will be sent and individuals responding will then followed up by telephone and invited to attend a screening visit at the Imperial CRF. They will be sent the participant information leaflet in advance of this meeting to give them time to consider the information. At this visit a member of the research team will go through the study procedure and answer any questions that the participant has.

Consent procedure:

Healthy volunteers who wish to participate in the study after considering the participant information leaflet will be consented by a trained researcher who will complete the eligibility screening for inclusion into the study.

Study Methodology:

10-15 healthy volunteers will be invited to participate in an exploratory study of the sensor device. On their screening visit routine blood tests will be performed to ensure that the participant is not anaemic and has no evidence of current infection. Before the study day the participant will be required to take 5 doses of oral penicillin to ensure that they are at steady state and to allow for stabilization of tissue distribution. Four of these doses will be taken at 6-hour intervals on the day before they attend the Imperial CRF. The final dose will be taken on the morning that they attend.

On arrival at the study centre the participant will have a microneedle biosensor sited for up to 12 hours whilst receiving antimicrobial therapy. The sensor will be sited peripherally (on an arm or leg). In a small number of cases the sensor may be sited centrally on the torso. These sensors are connected to potentiostat devices that records data, which can then be downloaded onto a computer for analysis.

Following arrival on the study day and placing of the sensor devices, a cannula will be sited for phlebotomy and a baseline beta-lactam antibiotic concentration will be taken. A microdialysis fibre will also be inserted peripherally into tissue close to the microneedle device to allow gold standard analysis of tissue antibiotic concentration. The participant will then undergo rich plasma drug sampling with up to 15 blood tests taken over a 6-12 hour period.

Each blood test will involve the collection of 3mL extra blood (\<1 teaspoons) via a cannula which will be cited on commencement of the study. Microdialysis may be performed in all participants who consent to this as a gold standard for determining tissue drug concentrations. If they do not consent for this, the study will be able to continue without microdialysis being performed. Participants will also be required to complete a visual analogue scale every hour testing their level of discomfort due to the microneedle sensor device and a member of the research team will document any redness or skin changes around the site of the device. A further dose of penicillin will be given approximately 6 hours into the study.

Time points for the blood sampling are planned to initially be taken at (0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 360, 480, 600, 720 minutes). However, following initial pharmacokinetic (PK) analysis a D-optimal design will be employed using Pmetrics and BestDose PK software to determine the optimal time points for blood PK analysis. This will be performed by a trained member of the research team.

Clinically relevant data including demographic, co-morbidity, and medication data will be collected by members of the research team from the participant.

Eligibility criteria: Inclusion Criteria:

* Adult \>18 years old
* Healthy with no evidence of active infection
* Previously received penicillin with no adverse effects

Exclusion Criteria:

* High risk of skin soft tissue infection or local skin and soft tissue infection near sensor site
* Previous history of allergies to adhesive strips or active dermatitis
* Penicillin allergy or previous adverse event whilst receiving penicillin
* Anaemia on screening bloods (defined as haemoglobin \<13 g/dL in males and \<12 g/dL in females)

Primary outcomes:
measure: Assessment of the Biosensors Ability to Track Phenoxymethylpenicillin Concentrations Compared to Observations Made by Microdialysis and Blood Sampling
timeFrame: Up to 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: NIHR Imperial CRF
Study officials:
affiliation: Health Protection Research Unit in HCAI & AMR
name: Alison H Holmes, MD MPH MBBS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rawson TM, Gowers SAN, Freeman DME, Wilson RC, Sharma S, Gilchrist M, MacGowan A, Lovering A, Bayliss M, Kyriakides M, Georgiou P, Cass AEG, O'Hare D, Holmes AH. Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. Lancet Digit Health. 2019 Nov;1(7):e335-e343. doi: 10.1016/S2589-7500(19)30131-1. Epub 2019 Sep 30.